1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,750 | 6,900 | 15:08 | |
| 6,750 | 6,900 | 15:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE IN THE AMOUNT OF UP TO US$50 MILLION UNDER THE ... | - | HKEx | ||
| Di | LEADS BIOLABS-B LBL-024 Clinical Study for Extrapulmonary Neuroendocrine Carcinoma Approved in Mainland China | 1 | AASTOCKS | ||
| Di | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR ADVANCED EXTRAPULMONARY ... | 1 | HKEx | ||
| Fr | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| Fr | LEADS BIOLABS-B (09887): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| Fr | LEADS BIOLABS-B (09887): POLL RESULTS OF THE ANNUAL GENERAL MEETING APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 14.05. | LEADS BIOLABS-B (09887): INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY | 2 | HKEx | ||
| 08.05. | LEADS BIOLABS-B (09887): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION AND PROPOSED IMPLEMENTATION OF H SHARE ... | - | HKEx | ||
| 06.05. | LEADS BIOLABS CO., LTD.: LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis | 1 | GlobeNewswire (USA) | ||
| 06.05. | LEADS BIOLABS-B Partner Dianthus Selects Three Priority Indications for LBL-047, Including Sjogren's Syndrome and Lupus | 3 | AASTOCKS | ||
| 06.05. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 PRIORITIZED FOR CLINICAL DEVELOPMENT IN SJOGREN'S DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, AND ... | 1 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 15, 2026 | - | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 FINAL FINANCIAL REPORT; (3) 2025 ANNUAL REPORT; (4) 2025 PROFIT DISTRIBUTION ... | 2 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): 2025 ANNUAL REPORT | 2 | HKEx | ||
| 24.04. | LEADS BIOLABS-B (09887): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.04. | LEADS BIOLABS CO., LTD.: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase - Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies | 1 | GlobeNewswire (USA) | ||
| 21.04. | LEADS BIOLABS-B: 1st Patient Enrolled in Phase II Trial of LBL-024 for 1st-Line Gastric or Gastroesophageal Junction Adenocarcinoma | 1 | AASTOCKS | ||
| 21.04. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN PHASE II TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) ... | 1 | HKEx |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 35,490 | -0,20 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| HCW BIOLOGICS | 2,440 | +0,41 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,890 | 0,00 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| COGENT BIOSCIENCES | 32,925 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,110 | 0,00 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| DYNE THERAPEUTICS | 17,560 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval | - 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,430 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) | ||
| TANGO THERAPEUTICS | 21,060 | -0,09 % | Tango Therapeutics Shares Fall 17% | ||
| RELAY THERAPEUTICS | 13,030 | +0,08 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| METAVIA | 2,895 | +0,17 % | MetaVia Inc.: MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update | 48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit
Key Milestone... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 335,45 | -0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ERASCA | 11,125 | +0,04 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,32 | 0,00 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| ENLIVEN THERAPEUTICS | 41,860 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Phase 1 data update for ELVN-001 expected mid-2026
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026
Strong balance... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 36,890 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
NANJING LEADS BIOLABS CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.